Efficacy and safety of extended-release oxcarbazepine (Oxtellar XR™) as adjunctive therapy in patients with refractory partial-onset seizures: a randomized controlled trial

OBJECTIVE: To evaluate the efficacy, tolerability, and safety of once-daily 1200 mg and 2400 mg SPN-804 (Oxtellar XR™, Supernus Pharmaceuticals), an extended-release tablet formulation of oxcarbazepine (OXC), added to 1-3 concomitant antiepileptic drugs (AEDs) in adults with refractory partial-onset...

Descripción completa

Detalles Bibliográficos
Autores principales: French, JA, Baroldi, P, Brittain, ST, Johnson, JK
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033571/
https://www.ncbi.nlm.nih.gov/pubmed/24359313
http://dx.doi.org/10.1111/ane.12207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033571/
https://www.ncbi.nlm.nih.gov/pubmed/24359313
http://dx.doi.org/10.1111/ane.12207

Ejemplares similares